Ascendis Pharma CFO updates Form 3 holdings
Ascendis Pharma A/S executive Scott Thomas Smith, EVP & Chief Financial Officer, has reported his equity holdings in an amended Form 3.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3/A
Rhea-AI Filing Summary
Ascendis Pharma A/S executive Scott Thomas Smith, EVP & Chief Financial Officer, has reported his equity holdings in an amended Form 3. He directly holds 4,017 Ordinary Shares.
He also holds Restricted Stock Units covering 9,552, 3,197 and 4,246 underlying Ordinary Shares, which begin vesting on March 1, 2027, with some vesting in two or three equal annual installments. In addition, he holds fully vested, currently exercisable warrants over 14,504, 22,755, 27,000, 45,000 and 45,000 Ordinary Shares at exercise prices ranging from $37.18 to $176.28 per share with expiration dates between 2027 and 2031. The filing lists holdings only and does not show any new purchases or sales.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
SMITH SCOTT THOMAS
Role
EVP & Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Warrants — 154,259 contracts (Direct);
Restricted Stock Units — 16,995 contracts (Direct);
Ordinary Shares — 4,017 shares (Direct)
Footnotes (5)
- F1. The warrants are fully vested and currently exercisable.
- F2. The restricted stock units vest on March 1, 2027 and have no expiration date.
- F3. Each restricted stock unit represents a contingent right to receive one Ordinary Share.
- F4. The restricted stock units vest in two equal annual installments beginning on March 1, 2027.
- F5. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.
Key Figures
Direct Ordinary Shares: 4,017 shares
RSUs grant 1 underlying shares: 9,552 shares
RSUs grant 2 underlying shares: 3,197 shares
+4 more
7 metrics
Direct Ordinary Shares
4,017 shares
Directly held by EVP & CFO after reported holdings
RSUs grant 1 underlying shares
9,552 shares
Restricted Stock Units, each for one Ordinary Share
RSUs grant 2 underlying shares
3,197 shares
Restricted Stock Units, vesting in two annual installments from March 1, 2027
RSUs grant 3 underlying shares
4,246 shares
Restricted Stock Units, vesting in three annual installments from March 1, 2027
Warrants @ $139.65
14,504 shares
Fully vested warrants exercisable at $139.65, expiring December 9, 2031
Warrants @ $176.28
22,755 shares
Fully vested warrants exercisable at $176.28, expiring December 10, 2030
Warrants @ $37.18
45,000 shares
Fully vested warrants exercisable at $37.18, expiring December 12, 2027
Key Terms
Restricted Stock Units, warrants, Ordinary Shares, vest, +1 more
5 terms
Restricted Stock Units financial
"The restricted stock units vest on March 1, 2027 and have no expiration date."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
warrants financial
"The warrants are fully vested and currently exercisable."
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
vest financial
"The restricted stock units vest in three equal annual installments beginning on March 1, 2027."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
expiration date financial
"The restricted stock units vest on March 1, 2027 and have no expiration date."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Ascendis Pharma (ASND) CFO Scott Thomas Smith report in this Form 3/A?
He reports his existing equity holdings in Ascendis Pharma, including Ordinary Shares, Restricted Stock Units and warrants. The filing is an amended Form 3 that updates his ownership details rather than showing new market transactions.
What Restricted Stock Units does the Ascendis Pharma (ASND) CFO hold?
He holds Restricted Stock Units tied to 9,552, 3,197 and 4,246 underlying Ordinary Shares. These RSUs begin vesting on March 1, 2027, with some vesting in two or three equal annual installments, each unit representing a right to receive one Ordinary Share.
When do the Ascendis Pharma (ASND) CFO’s Restricted Stock Units vest?
His Restricted Stock Units vest starting March 1, 2027. One grant vests fully on that date, while others vest in two or three equal annual installments beginning then, gradually converting into Ordinary Shares as vesting conditions are met over time.
What warrant positions does the Ascendis Pharma (ASND) CFO disclose?
He discloses fully vested, currently exercisable warrants over 14,504, 22,755, 27,000, 45,000 and 45,000 Ordinary Shares. Exercise prices range from $37.18 to $176.28 per share, with warrant expiration dates spanning from 2027 through 2031.
Does this Ascendis Pharma (ASND) Form 3/A show any insider buying or selling?
It does not show insider buying or selling. The entries are categorized as holdings, with zero buy or sell transactions in the transaction summary. The amendment focuses on detailing the CFO’s current share, RSU and warrant positions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
